SCHEMBL187396

SCHEMBL187396

CCOC(=O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
SOAT1 P35610 1/20 0.55
LMNA P02545 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ALOX15 P16050 1/20 0.42
MGAM O43451 1/20 0.42
GAA P10253 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
HDAC6 Q9UBN7 2/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
TRPA1 O75762 1/20 0.39
PKM P14618 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21357429 0.91 ALDH1A1 (0.50) ALDH1A1SOAT1LMNAHSD17B10ALOX15
SCHEMBL28434678 0.88 ALDH1A1 (0.52) ALDH1A1SOAT1LMNAHSD17B10ALOX15
SCHEMBL9639491 0.88 SOAT1 (0.68) ALDH1A1SOAT1LMNAHSD17B10ALOX15
SCHEMBL12315227 0.84 ALDH1A1 (0.60) ALDH1A1SOAT1LMNAHSD17B10ALOX15
Ethyl Acetate SCHEMBL28086033 0.83 ALDH1A1 (0.64) ALDH1A1SOAT1LMNAHSD17B10ALOX15
SCHEMBL12519845 0.81 HDAC6 (0.38) ALDH1A1SOAT1GAAHDAC6HDAC1
SCHEMBL2229434 0.80 ALDH1A1 (0.55) ALDH1A1SOAT1LMNAHSD17B10ALOX15
SCHEMBL9465250 0.80 ALDH1A1 (0.55) ALDH1A1SOAT1LMNAHSD17B10ALOX15
SCHEMBL12306239 0.80 ALDH1A1 (0.55) ALDH1A1SOAT1LMNAHSD17B10ALOX15
SCHEMBL29136421 0.80 ALDH1A1 (0.55) ALDH1A1SOAT1LMNAHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 840 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2418723-B1 NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEM CORP (JP) 2018-09-19 EP claimed
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 EP claimed
US-7687490-B2 2-thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2010-03-30 US claimed
EP-1870412-A1 2-THIOETHENYL CARBAPENEM DERIVATIVE MEIJI SEIKA KAISHA LTD. (JP) 2007-12-26 EP claimed
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2007-01-04 US claimed
US-5491167-A INHIBITORS OF CHOLESTEROL BIOSYNTHESIS SANKYO COMPANY, LIMITED (JP) 1996-02-13 US claimed
US-4731362-A Alkylcarbamoyloxymethylcephem compounds SHIONOGI & CO., LTD. (JP) 1988-03-15 US claimed
JP-4234491-A None JP disclosed
CN-115458808-B Method for producing lithium fluorosulfonate, nonaqueous electrolyte solution, and nonaqueous electrolyte secondary battery 三菱化学株式会社 2026-05-15 CN disclosed
US-12494506-B2 Nonaqueous electrolytic solution and energy device including the same MITSUBISHI CHEMICAL CORPORATION (JP) 2025-12-09 US disclosed
US-12456760-B2 Non-aqueous electrolyte solution for sodium ion secondary battery, and sodium ion secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2025-10-28 US disclosed
US-20250246686-A1 NON-AQUEOUS ELECTROLYTE AND NON-AQUEOUS ELECTROLYTE BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2025-07-31 US disclosed
EP-4519257-A1 PROCESS FOR THE PREPARATION OF PYROXASULFONE Adama Agan Ltd. (IL) 2025-03-12 EP disclosed
EP-0272583-A2 5-Substituted amino-4-hydroxy-pentenoic acid derivatives and their use Banyu Pharmaceutical Co., Ltd. (JP) 1988-06-29 EP disclosed
EP-0264106-A2 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use Banyu Pharmaceutical Co., Ltd. (JP) 1988-04-20 EP disclosed
US-4731362-A Alkylcarbamoyloxymethylcephem compounds SHIONOGI & CO., LTD. (JP) 1988-03-15 US disclosed
EP-0108942-B1 CEPHALOSPORIN DERIVATIVES, METHODS OF PRODUCTION THEREOF AND PROPHYLACTIC AND THERAPEUTIC AGENTS FOR BACTERIAL INFECTION KYOTO PHARMA IND (JP) 1988-03-02 EP disclosed
EP-0233946-A1 CHROMOGLYCIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND MEDICINAL COMPOSITION Kyoto Pharmaceutical Industries, Ltd. (JP) 1987-09-02 EP disclosed
US-4605651-A BACTERICIDES KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1986-08-12 US disclosed
EP-0108942-A2 Cephalosporin derivatives, methods of production thereof and prophylactic and therapeutic agents for bacterial infection Kyoto Pharmaceutical Industries, Ltd. (JP) 1984-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MTAP, BLVRB, BPGM ALDH1A1 1182/4885SOAT1 3551/4885LMNA 899/4885
US-12456760-B2 Non-aqueous electrolyte solution for sodium ion secondary battery, and sodium ion secondary battery NHERF1, NAP1L1, NAF1 ALDH1A1 2234/4885SOAT1 402/4885LMNA 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.